Sökning: id:"swepub:oai:gup.ub.gu.se/195313" >
5 year efficacy of ...
5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: A cluster-randomised, double-blind, placebo-controlled trial
-
Bhattacharya, S. K. (författare)
-
Sur, D. (författare)
-
Ali, M. (författare)
-
visa fler...
-
Kanungo, S. (författare)
-
You, Y. A. (författare)
-
Manna, B. (författare)
-
Sah, B. (författare)
-
Niyogi, S. K. (författare)
-
Park, J. K. (författare)
-
Sarkar, B. (författare)
-
Puri, M. K. (författare)
-
Kim, D. R. (författare)
-
Deen, J. L. (författare)
-
- Holmgren, Jan, 1944 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi,Institute of Biomedicine, Department of Microbiology and Immunology
-
Carbis, R. (författare)
-
Dhingra, M. S. (författare)
-
Donner, A. (författare)
-
Nair, G. B. (författare)
-
Lopez, A. L. (författare)
-
Wierzba, T. F. (författare)
-
Clemens, J. D. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2013
- 2013
- Engelska.
-
Ingår i: Lancet. Infectious Diseases. - 1473-3099 .- 1474-4457. ; 13:12, s. 1050-1056
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Efficacy and safety of a two-dose regimen of bivalent killed whole-cell oral cholera vaccine (Shantha Biotechnics, Hyderabad, India) to 3 years is established, but long-term efficacy is not. We aimed to assess protective efficacy up to 5 years in a slum area of Kolkata, India. Methods: In our double-blind, cluster-randomised, placebo-controlled trial, we assessed incidence of cholera in non-pregnant individuals older than 1 year residing in 3933 dwellings (clusters) in Kolkata, India. We randomly allocated participants, by dwelling, to receive two oral doses of modified killed bivalent whole-cell cholera vaccine or heat-killed Escherichia coli K12 placebo, 14 days apart. Randomisation was done by use of a computer-generated sequence in blocks of four. The primary endpoint was prevention of episodes of culture-confirmed Vibrio cholerae O1 diarrhoea severe enough for patients to seek treatment in a health-care facility. We identified culture-confirmed cholera cases among participants seeking treatment for diarrhoea at a study clinic or government hospital between 14 days and 1825 days after receipt of the second dose. We assessed vaccine protection in a per-protocol population of participants who had completely ingested two doses of assigned study treatment. Findings: 69 of 31932 recipients of vaccine and 219 of 34968 recipients of placebo developed cholera during 5 year follow-up (incidence 2·2 per 1000 in the vaccine group and 6·3 per 1000 in the placebo group). Cumulative protective efficacy of the vaccine at 5 years was 65% (95% CI 52-74; p<0·0001), and point estimates by year of follow-up suggested no evidence of decline in protective efficacy. Interpretation: Sustained protection for 5 years at the level we reported has not been noted previously with other oral cholera vaccines. Established long-term efficacy of this vaccine could assist policy makers formulate rational vaccination strategies to reduce overall cholera burden in endemic settings. Funding: Bill & Melinda Gates Foundation and the governments of South Korea and Sweden. © 2013 Elsevier Ltd.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Infectious Medicine (hsv//eng)
Nyckelord
- bivalent killed whole cell oral cholera vaccine
- cholera vaccine
- inactivated vaccine
- placebo
- shanchol
- unclassified drug
- adolescent
- article
- child
- cholera
- controlled study
- double blind procedure
- drug efficacy
- Escherichia coli K 12
- follow up
- human
- incidence
- India
- infant
- infection rate
- infectious diarrhea
- major clinical study
- outcome assessment
- preschool child
- priority journal
- randomized controlled trial
- school child
- vaccination
- Administration
- Oral
- Child
- Preschool
- Cholera Vaccines
- Cluster Analysis
- Diarrhea
- Double-Blind Method
- Humans
- Placebos
- Vaccines
- Inactivated
- Vibrio cholerae O1
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Bhattacharya, S. ...
-
Sur, D.
-
Ali, M.
-
Kanungo, S.
-
You, Y. A.
-
Manna, B.
-
visa fler...
-
Sah, B.
-
Niyogi, S. K.
-
Park, J. K.
-
Sarkar, B.
-
Puri, M. K.
-
Kim, D. R.
-
Deen, J. L.
-
Holmgren, Jan, 1 ...
-
Carbis, R.
-
Dhingra, M. S.
-
Donner, A.
-
Nair, G. B.
-
Lopez, A. L.
-
Wierzba, T. F.
-
Clemens, J. D.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Infektionsmedici ...
- Artiklar i publikationen
-
Lancet. Infectio ...
- Av lärosätet
-
Göteborgs universitet